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Abstract
Intermediary metabolites of cholesterol synthetic pathway are involved in cell proliferation. Lovastatin, an inhibitor of
3-hydroxy-3-methylglutaryl coenzyme A reductase, blocks mevalonate synthesis, and has been shown to inhibit mesangial
cell proliferation associated with diverse glomerular diseases. Since inhibition of farnesylation and plasma membrane
anchorage of the Ras proteins is one suggested mechanism by which lovastatin prevents cellular proliferation, we investigated
the effect of lovastatin and key mevalonate metabolites on the activation of mitogen-activated protein kinase (MAP kinase)
and Ras in murine glomerular mesangial cells. The preincubation of mesangial cells with lovastatin inhibited the activation of
MAP kinase stimulated by either FBS, PDGF, or EGF. Mevalonic acid and farnesylpyrophosphate, but not cholesterol or
LDL, significantly prevented lovastatin-induced inhibition of agonist-stimulated MAP kinase. Lovastatin inhibited agonist-
induced activation of Ras, and mevalonic acid and farnesylpyrophosphate antagonized this effect. Parallel to the MAP
kinase and Ras data, lovastatin suppressed cell growth stimulated by serum, and mevalonic acid and farnesylpyrophosphate
prevented lovastatin-mediated inhibition of cellular growth. These results suggest that lovastatin, by inhibiting the synthesis
of farnesol, a key isoprenoid metabolite of mevalonate, modulates Ras-mediated cell signaling events associated with
mesangial cell proliferation. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The proliferation of glomerular mesangial cells
and exaggerated expression of extracellular matrix
proteins (ECM) are principal histopathological ¢nd-
ings seen in diverse human and experimental renal
diseases [1]. Increased expression of peptide growth
factors has been thought to contribute to the mesan-
gial hypercellularity seen in diverse glomerular dis-
eases ([2^4] and references therein). Additionally, a
growing body of evidence suggests a pathobiological
role for cholesterol and atherogenic lipoproteins in
mesangial hypercellularity and the development of
glomerular disease [5^9]. Furthermore, the adminis-
tration of inhibitors of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase, the rate limiting
enzyme in cholesterol biosynthetic pathway, to ani-
mals with experimental renal disease signi¢cantly in-
0167-4889 / 99 / $ ^ see front matter ß 1999 Elsevier Science B.V. All rights reserved.
PII: S 0 1 6 7 - 4 8 8 9 ( 9 9 ) 0 0 0 0 7 - 5
Abbreviations: MAP kinase, mitogen-activated protein ki-
nase; ECM, extracellular matrix proteins; HMG-CoA, 3-hy-
droxy-3-methylglutaryl coenzyme A
* Corresponding author. Fax: +1-562-494-5675.
1 Michael A. Kirschenbaum, deceased.
BBAMCR 14443 2-3-99
Biochimica et Biophysica Acta 1449 (1999) 137^149
hibited mesangial hypercellularity, ECM expansion
and prevented the progression of glomerular disease
[10^12]. In vitro studies have also shown that the
inhibition of cholesterol synthesis by HMG-CoA re-
ductase inhibitors (e.g., compactin, lovastatin) ar-
rested G1 phase of the cell cycle and manifested in
an inhibition of DNA synthesis and cell proliferation
in various cell types including mesangial cells [13^19],
suggesting a key role for cholesterol synthetic path-
way in cellular growth.
Although the intracellular mitogenic signaling
mechanisms a¡ected by the inhibition of mevalonic
acid synthesis are not clearly understood, the alter-
ations in the production of farnesol, one of the key
intermediates of mevalonic acid metabolism, has
been implicated in this process. Farnesol, an impor-
tant isoprenoid intermediate, is involved in the post-
translational processing of various cellular GTP-
binding proteins (e.g., RAS family of proteins,
[20,21]). Ras proteins are posttranslationally modi-
¢ed by the addition of isoprenoid units and this fa-
cilitates the binding of these proteins to the plasma
membrane [22,23]. The membrane-associated p21
Ras binds with guanine nucleotides and through
low intrinsic GTPase activity cycles between an ac-
tive GTP-bound form and an inactive GDP-bound
form. Ras proteins in their active GTP bound state
stimulate the binding to and activation of Raf, and
in turn activate mitogen-activated protein kinase
(MAP kinase) cascade [24^26]. Previous studies
have indicated that the treatment of cells with lova-
statin, by inhibiting the synthesis of farnesylpyro-
phosphate, decreased the isoprenylation of p21 Ras
and suggested that this property of lovastatin may, at
least in part, be associated with cellular proliferation
[27,28]. However, none of the previous studies ad-
dressed whether lovastatin would modulate Ras
functioning and the activation of Ras through ex-
change of GTP for GDP and in turn modulate
MAP kinase cascade mitogenic signaling in intact
cells containing normal nonmutated forms of Ras.
The activation of MAP kinase cascade, through
protein tyrosine kinase and Ras-mediated pathways,
is one of the major intracellular signaling pathways
that integrate diverse signal transduction events as-
sociated with various cellular responses including mi-
togenesis and di¡erentiation ([29,30] and references
therein). MAP kinases are serine threonine cytoplas-
mic kinases that are activated by mitogenic stimuli
through phosphorylation of tyrosine and threonine
residues [29,30]. Activated cytoplasmic MAP kinases
have been shown to translocate into the nucleus and
activate various transcription factors and protoonco-
genes associated with cell growth and proliferation
[31,32]. In the present studies, in order to understand
the role of the cholesterol synthetic pathway in the
functioning of the growth factor signal transduction
cascade, we examined the agonist-mediated activa-
tion of Ras and the MAP kinase, and cellular growth
in glomerular mesangial cells treated with the HMG-
CoA reductase inhibitor lovastatin. Furthermore,
studies were designed to identify intermediates of
cholesterol synthetic pathway that are involved in
intracellular signaling pathways and cell prolifera-
tion. This study represents the ¢rst comprehensive
investigation on the interaction of the cholesterol
synthetic pathway with the MAP kinase cascade in-
volved in mitogenic signaling and mesangial cell pro-
liferation.
2. Materials and methods
2.1. Materials
Goat polyclonal antimouse p42-MAP kinase anti-
body was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Anti-Ras antibody (clone Y 13-
259) was obtained from Cal Biochem (San Diego,
CA). [32P]ATP was obtained from DuPont New Eng-
land Nuclear Research Products (Boston, MA). Pro-
tein-A Sepharose, myelin basic protein, fetal bovine
serum, mevalonic acid, farnesylpyrophosphate, and
other chemicals were purchased from Sigma Chem-
ical Co. (St. Louis, MO). Lovastatin was provided by
Merck Research Laboratories (Rahway, NJ). All
other chemicals used were of analytical grade.
2.2. Cell culture and treatment
The murine mesangial cell line (stably trans-
formed, isolated from normal glomeruli of mice
transgenic for the early region of the DNA tumor
virus, simian virus 40; American Type Culture Col-
lection, Rockville, MD) were grown in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) supplemented
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with 5% fetal bovine serum (FBS) in 30-mm 6-well
cluster dishes. When cell monolayer was approxi-
mately 70% con£uent, the medium was replaced by
serum-free DMEM containing a mixture of insulin,
transferrin, and selenium (5 WM, 5 WM, and 5 nM,
respectively). Lovastatin, mevalonic acid, farnesyl-
pyrophosphate, low-density lipoprotein (LDL), and
cholesterol were added as appropriate. A 10-mM
stock solution of lovastatin was prepared by dissolv-
ing 18 mg of lovastatin in alcoholic NaOH (360 Wl
ethanol plus 180 Wl of 0.6 N NaOH [33]) and diluting
to 4.5 ml with distilled water. The pH of the lova-
statin solution was adjusted to 8.0. Further dilutions
were made in DMEM. Mevalonic acid was dissolved
in phosphate-bu¡ered saline (PBS) and farnesylpyro-
phosphate was diluted in PBS. At selected time in-
tervals, after the incubation with lovastatin, cells
were stimulated with either FBS (5%, 15 min), plate-
let-derived growth factor (PDGF, 25 ng/ml, 10 min),
or epidermal growth factor (EGF, 100 ng/ml, 10
min) by directly adding these agonists to the me-
dium.
After incubating for selected time intervals, the
medium was removed, and the cells were washed
with 1 ml of cold Hank’s balanced salt solution
(HBSS) and scraped into 0.5 ml of MAP kinase lysis
bu¡er (50 mM Hepes (pH 7.5), 100 mM NaCl,
2 mM EDTA, 1 mM vanadate, 40 mM paranitro-
phenyl phosphate, 1 WM pepstatin, 1 Wg/ml leupep-
tin, 2 Wg/ml aprotinin, and 1% NP-40). After a brief
centrifugation, the supernatant (cell lysate) was ali-
quoted and stored at 380‡C for not more than 3 days
before assaying the MAP kinase activity.
2.3. Immunoprecipitation and assay of p42 MAP
kinase
Immunoprecipitation of p42 MAP kinase in cell
lysate (20^30 Wg protein) was performed by incubat-
ing protein-A Sepharose-conjugated goat polyclonal
anti p42 MAP kinase antibody (0.4 Wg antibody and
50% protein-A Sepharose, 18 h, at 4‡C) for 2 h at
4‡C. The protein-A Sepharose pellet was then re-
trieved by centrifugation and washed twice with
MAP kinase lysis bu¡er and twice with a solution
of 10 mM magnesium acetate, and 10 mM Hepes,
pH 7.5. Kinase activity of the immune complex was
assayed with myelin basic protein as a substrate in a
reaction mixture containing 7.5 mM Hepes (pH 7.5),
10 mM magnesium acetate, 50 WM ATP and 4 WCi
[32P]ATP [34]. The reaction was performed at 30‡C
for 20 min and was terminated by the addition of 20
Wl of 3ULaemmli sample bu¡er. The contents were
then heated at 80‡C for 5 min and were separated by
polyacrylamide (10%) gel electrophoresis. Electro-
phoresis was continued until free ATP drained into
the electrode bu¡er. The gel was stained, dried and
¢rst exposed to X-ray ¢lm for 1^4 h. For determin-
ing the protein content, 50 Wl of the cell lysate was
precipitated with 1 ml of 10% perchloric acid over-
night and protein content in the precipitate was as-
sayed by Lowry method using bovine serum albumin
as a standard. The quantitative analysis of MAP
kinase activity was done by cutting out the myelin
basic protein bands from the dried gels and measur-
ing the radioactivity of [32P]ATP incorporated into
myelin basic protein. MAP kinase activity was ex-
pressed as pmol phosphate per mg cellular lysate
protein/20 min.
2.4. Metabolic labeling and Ras activation assay
Ras activation analysis was done by the method of
Downard et al. [35]. Cells (5U105) were seeded in
6-well plates and grown for 24 h in DMEM+5%
FBS media. The medium was then replaced by 2 ml
of low phosphate DMEM (Gibco’S phosphate free
medium supplemented with 5% of regular DMEM)
containing 300 WCi of [32P]orthophosphate. After 2 h
of labeling, lovastatin, mevalonic acid, or farnesylpyr-
ophosphate were added as appropriate. Seven hours
later the cells were stimulated with FBS (2 min and
5 min) or PDGF (5 min). The cells were then washed
with PBS, and scraped in 0.3 ml of Ras lysis bu¡er
(Hepes (pH 7.4), 50 mM; NaCl, 100 mM; MgCl2,
5 mM; leupeptin, 10 Wg/ml; aprotinin, 10 Wg/ml,
phenylmethylsulfonyl £uoride, 9 Wg/ml, and Triton
X-100, 1%, BSA, 1 mg/ml; and benzamadine, 10
mM). The cell lysate was ¢rst mixed with an equal
volume of a solution of 1 M NaCl, 0.1% SDS, and
1% sodium deoxycholate, and was then treated with
BSA coated charcoal. After centrifugation, the super-
natant was immunoprecipitated with anti-Ras anti-
body (0.5 Wg, conjugated to protein-A Sepharose) by
mixing for 40 min at 4‡C. The beads were washed
four times with Ras lysis bu¡er containing no pro-
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tease inhibitors or detergent. The guanine nucleotides
were then eluted with potassium phosphate bu¡er
(1 M, pH 3.4), by heating at 65‡C for 10 min.
GTP and GDP were separated by thin-layer chroma-
tography on polyethyleneimine cellulose plates [35]
and were detected by autoradiography.
2.5. Western blot analysis of p21 Ras
Membrane associated p21 Ras was measured
by Western blot analysis using plasma membranes.
Cells were seeded at a density of 0.3U106 per dish
in 30-mm cluster dishes and grown for 24 h in
DMEM+5% FBS media. The medium was replaced
by DMEM containing insulin/transferrin/selenium
mixture, appropriate concentrations of lovastatin
(20 WM) or lovastatin (20 WM)+mevalonic acid
(5 mM) added, and incubated for 7 h. The cells were
washed and scraped into PBS, sonicated for 10 s, and
the plasma membranes were isolated by centrifuga-
tion at 100 000Ug. The membrane fraction was solu-
bilized in Ras processing bu¡er (50 mM Hepes (pH
7.5), 10 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 1%
Triton X-100, 10% glycerol, 25 Wg/ml leupeptin,
1 mg/ml soybean trypsin inhibitor, 10 Wg/ml aproti-
nin [36]). Aliquots of solubilized membranes were
subjected to electrophoresis on 12% SDS^PAGE,
transferred onto nitrocellulose membranes, and im-
munoblotted with anti-Ras antibody (Y13-259). The
membrane associated p21 Ras was detected by en-
hanced chemiluminescent detection system.
2.6. Mesangial cell proliferation assay
Mesangial cells were grown in DMEM+5% FBS
for 24 h to attain 60^70% con£uence, and were made
quiescent by incubating in FBS-free DMEM for 24
h. The media was replaced with DMEM containing
FBS (5%) and lovastatin (5 WM), and either meva-
lonic acid (5 mM) or farnesylpyrophosphate (5 WM).
The cells were incubated for 24 h, washed, trypsi-
nized, and the cell number was counted using a he-
macytometer.
2.7. Statistical analysis
Results are presented as mean values þ standard
error (S.E.) for 3^4 separate experiments each as-
sayed in triplicate. A Student’s t-test was used to
compare the mean values of control and experimen-
tal groups, and a P value of less than 0.05 was con-
sidered signi¢cant.
3. Results
Previously, we observed that the basal levels of
p44 MAP kinase activity in murine mesangial cells
was severalfold lower than that of p42 MAP kinase.
In this study, we examined the role of inhibition of
cholesterol synthetic pathway on mesangial cell p42
MAP kinase cascade and cell proliferation.
3.1. Lovastatin inhibits FBS-induced MAP kinase
activity
Initial studies were performed to determine the
incubation time response of lovastatin on MAP ki-
nase activity by incubating mesangial cells with lova-
Fig. 1. Dose response of the e¡ect of lovastatin on FBS-in-
duced activation of mesangial cell MAP kinase. Mesangial cells
were incubated with lovastatin (5^20 WM) for 7 h in DMEM
containing insulin, transferrin, and selenium, and were stimu-
lated with FBS (5% ¢nal) for 15 min. P42 MAP kinase was de-
termined as described in Section 2. Results are from a single
representative experiment of three separate studies each assayed
in triplicate. Comparisons were made between control (without
lovastatin treatment) and FBS-treated control cells, and be-
tween FBS-treated control cells and FBS+lovastatin-treated
cells. Lovastatin did not signi¢cantly alter MAP kinase activity
in control cells. The MAP kinase activity (pmol/mg protein) in
control, control+5 WM lovastatin, and control+20 WM lovasta-
tin were 20.98 þ 2.4, 17.87 þ 5.2, and 19.23 þ 4.6, respectively.
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statin for 3, 7, and 12 h. Incubation of mesangial
cells with lovastatin (20 WM) for 3 h did not signi¢-
cantly a¡ect the activation of MAP kinase by FBS,
but incubation for 7-h and 12-h time periods de-
creased the activity by 1.6-fold. In all of the remain-
ing experiments, 7 h incubation time was used. Dur-
ing 7 h of incubation, lovastatin did not alter either
the viability (as measured by trypan blue exclusion)
or cell number when compared to control cells.
The dose response of lovastatin on MAP kinase
activity was performed by incubating mesangial cells
with various doses of lovastatin (5^20 WM) for 7 h.
Stimulation of mesangial cells with FBS, induced
MAP kinase activity by 3.5-fold as compared to con-
trols without lovastatin treatment (Fig. 1). However,
the preincubation of mesangial cells with lovastatin
(5^20 WM), dose-dependently reduced MAP kinase
induction by FBS by 1.6^2.2-fold when compared
to 3.5-fold induction by FBS in control cells (Fig.
1). Comparative analysis of MAP kinase data from
various experiments indicated that lovastatin, at a
20-WM dose, nearly completely attenuated FBS-
mediated induction of MAP kinase. Lovastatin alone
had no signi¢cant e¡ect on MAP kinase activity in
control cells. The MAP kinase activity (pmol/mg
protein) in control, control+5 WM lovastatin, and
control+20 WM lovastatin were 20.98 þ 2.4,
17.87 þ 5.2, and 19.23 þ 4.6, respectively.
3.2. Mevalonic acid and farnesylpyrophosphate
prevent lovastatin-mediated inhibition of
FBS-induced MAP kinase
Since lovastatin, an HMG-CoA reductase inhibi-
tor, speci¢cally inhibits mevalonic acid synthesis, fur-
ther studies were designed to examine whether exog-
enous mevalonic acid could prevent lovastatin-
mediated inhibition of FBS-induced MAP kinase.
Preincubation of mesangial cells with mevalonic
acid, at 0.1^5 mM doses, completely prevented lov-
astatin-mediated inhibition of MAP kinase activity
(Fig. 2A). Mevalonic acid, at all doses of 0.1^5
mM, had an approximately similar e¡ect in antago-
C
Fig. 2. (A) E¡ect of mevalonic acid on the inhibition of MAP
kinase activation by lovastatin. Cells were incubated with lova-
statin (5 WM) for 7 h. Mevalonic acid (0.1^5 mM) dissolved in
PBS was added to appropriate dishes at the beginning of the
incubation. Cells were then stimulated with FBS (5%) for 15
min and the MAPK activity was determined as described in
Section 2. (B) E¡ect of farnesyl pyrophosphate on lovastatin-
mediated inhibition of MAP kinase. Cells were incubated with
lovastatin (5 WM) for 7 h. Farnesyl pyrophosphate (FPP, 1^5
WM) dissolved in DMEM was added to the appropriate dishes
at the time of addition of lovastatin. Methanol (0.2%) was
added to the dishes (not containing FPP) to account for the
presence of methanol in the commercial preparation of FPP.
Cells were stimulated with FBS for 15 min, lysed, and the
MAP kinase activity was determined. Results are from a single
representative experiment of three separate studies each assayed
in triplicate. The P values were evaluated by comparing the val-
ues of control and those of FBS; FBS and FBS+lovastatin;
FBS+lovastatin and FBS+lovastatin+mevalonic acid; FBS+lo-
vastatin and FBS+lovastatin+Farnesyl pyrophosphate-treated
groups.
BBAMCR 14443 2-3-99
B.V. Bassa et al. / Biochimica et Biophysica Acta 1449 (1999) 137^149 141
nizing the e¡ects of lovastatin. Similarly, mevalonic
acid (0.1^5 mM) also prevented the inhibition of
FBS-induced MAP kinase activity by a 20-WM dose
of lovastatin (data not shown). In order to exclude
the possibility that mevalonic acid in itself increased
the MAP kinase activity in lovastatin treated cells,
we conducted experiments to assess the e¡ect of
5 mM mevalonic acid on MAP kinase activity in
lovastatin (5^20 WM)-treated cells that were not
stimulated with FBS. The results showed that the
addition of either lovastatin alone or in combination
with mevalonic acid (i.e., lovastatin+mevalonic acid)
did not increase MAP kinase activity when compared
to controls (data not shown).
Since farnesol, an isoprenoid intermediate of me-
valonic acid metabolic pathway, is implicated in the
isoprenylation of Ras proteins, further studies were
performed to examine the e¡ect of exogenous farne-
sylpyrophosphate on lovastatin-mediated inhibition
of MAP kinase activity. Preincubation of mesangial
cells with farnesylpyrophosphate (1^5 WM) also com-
pletely prevented lovastatin-mediated inhibition of
MAP kinase (Fig. 2B). Farnesylpyrophosphate, at
doses of 1^5 WM, had an approximately similar e¡ect
in completely blocking lovastatin-mediated inhibition
of MAP kinase activity (Fig. 2B). Additional experi-
ments were done to examine the e¡ect of mevalonic
acid and farnesylpyrophosphate on MAP kinase ac-
tivity in control cells (without lovastatin treatment).
The results indicated that mevalonic acid increased
MAP kinase activity by 2-fold (P6 0.05), and farne-
sylpyrophosphate increased MAP kinase activity by
1.4-fold (statistically not signi¢cant). The MAP ki-
nase activity (pmol/mg protein) in control, control+
mevalonic acid (5 mM), and control+farnesylpyro-
phosphate (5 WM) were 20.98 þ 2.4, 46.07 þ 6.4, and
28.53 þ 6.7, respectively.
Additional experiments using primary cultures of
rat glomerular mesangial cells were performed to val-
idate the e¡ects of lovastatin in stably transformed
mesangial cells. Incubation of primary cultures of
mesangial cells with lovastatin also signi¢cantly in-
hibited FBS-induced MAP kinase activity, and both
mevalonic acid or farnesylpyrophosphate prevented
this e¡ect. The MAP kinase activity (pmol/mg pro-
tein) in control, FBS, lovastatin (20 WM)+FBS, lov-
astatin+FBS+mevalonic acid (5 mM), and lovasta-
tin+FBS+farnesylpyrophosphate (5 WM) were
18.63 þ 1.33, 105.23 þ 4.74, 71.37 þ 3.53, 110.4 þ 7.63,
and 114.6 þ 6.72, respectively. In all of the following
experiments, murine mesangial cell line was used to
identify the participation of speci¢c cholesterol syn-
thetic intermediates in Ras and MAP kinase signal-
ing.
3.3. Lovastatin inhibits growth factor-induced MAP
kinase activation: regulatory role of mevalonic
acid and farnesylpyrophosphate
Additional studies were performed to examine the
e¡ects of lovastatin on speci¢c growth factor (e.g.,
PDGF and EGF) induced MAP kinase activity. The
results indicated that the preincubation of mesangial
cells with lovastatin (20 WM) signi¢cantly inhibited
Table 1
E¡ect of lovastatin on PDGF and EGF-induced mesangial call MAP kinase activity: role of mevalonic acid and farnesyl pyrophos-
phate
Agonists MAP kinase activity
(pmol phosphate/mg protein)
Agonists MAP kinase activity
(pmol phosphate/mg protein)
None (control) 10.5 þ 1.3 None (control) 10.5 þ 1.3
PDGF 54.4 þ 5.1 EGF 64.1 þ 0.5
Lov+PDGF 30.1 þ 0.9 Lov+EGF 36.9 þ 2.1
Lov+PDGF+MEV 49.9 þ 0.5 Lov+EGF+MEV 54.0 þ 1.5
Lov+PDGF+FPP 48.8 þ 1.1 Lov+EGF+FPP 52.7 þ 1.8
Mesangial cells were incubated in the presence or absence of lovastatin (Lov, 20 WM) in serum-free DMEM for 7 h, and then stimu-
lated with either PDGF (25 ng/ml) or EGF (100 ng/ml) for 10 min. In additional experiments, cells were co-incubated with lovastatin
and mevalonic acid (MEV, 5 mM) or lovastatin and farnesyl pyrophosphate (FPP, 5 WM) for 7 h, and then stimulated with either
PDGF or EGF. MAP kinase activity in cell lysate was determined as described in Section 2. Data are from a representative experi-
ment.
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either PDGF or EGF-induced MAP kinase activity
(Table 1). Stimulation of mesangial cells with PDGF
BB (25 ng/ml) for 10 min induced MAP kinase ac-
tivity by 5.2-fold when compared to basal activity in
control cells. When mesangial cells were preincu-
bated with lovastatin (20 WM), the MAP kinase in-
duction by PDGF was only 2.8-fold as compared to
a 5.2-fold increase in PDGF-treated control cells
(Table 1). Stimulation of mesangial cells with EGF
(100 ng/ml) for 10 min increased MAP kinase activ-
ity by approximately 5.8-fold (Table 1). Preincuba-
tion of mesangial cells with lovastatin (20 WM) for 7
h signi¢cantly inhibited EGF-induced MAP kinase
activity. Furthermore, coincubation of either meva-
lonic acid (5 mM) or farnesylpyrophosphate (5 WM)
with lovastatin (20 WM) largely prevented lovastatin-
mediated inhibition of MAP kinase activation (Table
1).
3.4. LDL or cholesterol do not a¡ect lovastatin-
mediated inhibition of FBS-induced MAP kinase
activity
Additional studies were performed to determine
whether exogenous cholesterol or delivery of choles-
terol to cells through LDL would prevent lovastatin-
mediated inhibition of mesangial cell MAP kinase.
Since LDL is a physiological source for a majority
of cellular cholesterol, studies were performed to ex-
amine the e¡ect of LDL on lovastatin-mediated in-
hibition of MAP kinase activity. Mesangial cells were
preincubated with LDL (10^50 Wg/ml) and lovastatin
(5 or 20 WM) for 7 h and stimulated with FBS for 15
min. LDL, at 10^50 Wg/ml doses, did not prevent
lovastatin (5 WM)-mediated inhibition of MAP ki-
nase activity (Fig. 3). Additionally, LDL (10^50 Wg/
ml) had no e¡ect on the inhibition of MAP kinase by
20 WM lovastatin (data not shown). We further ex-
tended these studies to examine whether prolonged
incubation of cells with LDL is required for its e¡ect
on lovastatin-mediated alterations in MAP kinase. In
these studies, mesangial cells were preincubated with
LDL (10^50 Wg/ml) for 12 h prior to the addition of
lovastatin. After 7 h of incubation with lovastatin (5
or 20 WM), cells were stimulated with FBS. Similar to
previous studies, preincubation of mesangial cells for
12 h with LDL also did not alter lovastatin’s e¡ect
on MAP kinase activity (data not shown). Addition-
al studies were designed to examine the direct e¡ects
of exogenous cholesterol on MAP kinase. In these
studies, mesangial cells were coincubated with cho-
lesterol (12.5^25 Wg/ml) and lovastatin (5 or 20 WM)
for 7 h prior to the stimulation with FBS. Parallel to
the LDL studies, the results indicated that the incu-
bation of cells with cholesterol (12.5 and 25 Wg/ml)
did not signi¢cantly alter lovastatin-mediated inhibi-
tion of FBS-induced MAP kinase activity (data not
shown). Additional experiments were done to exam-
ine the e¡ect of cholesterol or LDL on MAP kinase
in control (without lovastatin treatment) cells. Under
the experimental conditions used, cholesterol or LDL
had no signi¢cant e¡ect on MAP kinase activity in
control cells. The MAP kinase activity (pmol/mg
protein) in control, control+cholesterol (25 Wg/ml),
and control+LDL (50 Wg/ml) were 11.37 þ 4.04,
13.63 þ 1.44, and 9.17 þ 0.6, respectively.
Fig. 3. E¡ect of low-density lipoproteins (LDL) on the lovasta-
tin-mediated inhibition of MAP kinase in mesangial cells. Cells
were incubated with LDL (10^50 Wg/ml) and lovastatin (5 WM)
for 7 h, and were stimulated with FBS for 15 min. MAP kinase
activity was determined as described in Section 2. Results are
from a single representative experiment of two separate studies
each assayed in triplicate. The P values were evaluated by com-
paring the values of control and those of FBS; FBS and
FBS+lovastatin; FBS+lovastatin and FBS+lovastatin+LDL
treated groups. Under the experimental conditions used, choles-
terol or LDL had no signi¢cant e¡ect on MAP kinase activity
in control cells. The MAP kinase activity (pmol/mg protein) in
control, control+cholesterol (25 Wg/ml), and control+LDL (50
Wg/ml) were 11.37 þ 4.04, 13.63 þ 1.44, and 9.17 þ 0.6, respec-
tively.
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Fig. 4. E¡ect of lovastatin on the activation of Ras by PDGF (A) or FBS (B), and membrane Ras distribution (C). (A,B) Cells were
grown in 5% FBS medium for 24 h. The medium was then replaced by low phosphate medium (2 ml) containing 300 WCi of
[32P]orthophosphate. Two hours later lovastatin (Lov, 20 WM), mevalonic acid (Mev, 5 mM) and farnesyl pyrophosphate (FPP, 5 WM)
were added to appropriate dishes. Seven hours later the cells were stimulated with PDGF (A) or FBS (B) for 5 min, and were
processed for the assay of Ras activation as described in Section 2. (C) Membrane distribution of p21 Ras. Cells were incubated for
7 h with lovastatin (20 WM) in the presence or absence of mevalonic acid (5 mM). After sonication, plasma membranes were prepared
by centrifugation at 100 000Ug. Membrane distribution of p21Ras was measured by Western blot analysis as described in Section 2.
The autoradiograms are representative of two separate studies.
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3.5. Lovastatin inhibits activation of Ras induced by
FBS and PDGF: regulatory role of mevalonic
acid and farnesylpyrophosphate
Since farnesol, an intermediate precursor of cho-
lesterol synthetic pathway, has been implicated in
farnesylation of Ras and its anchorage to the plasma
membrane, we examined whether inhibition of farne-
sylpyrophosphate synthesis by lovastatin modulates
the activation of Ras. The activation of Ras induced
by agonists was assessed by measuring the associa-
tion of GTP with immunoprecipitated Ras (in whole
cell lysate) in mesangial cells treated with lovastatin
in the absence or presence of either mevalonic acid or
farnesylpyrophosphate. In view of the instability of
the Ras-bound GTP that requires rapid processing,
we used whole cell lysate instead of membrane frac-
tion in our Ras activation assays. It is known that
only the membrane bound Ras is involved in GTP
exchange and Ras-related signaling. The incubation
of mesangial cells with lovastatin (20 WM) for 7 h
nearly completely blocked Ras activation induced
by PDGF (25 ng/ml, for 5 min, Fig. 4A). The coin-
cubation of mesangial cells with mevalonic acid
(5 mM) nearly completely eliminated lovastatin-
mediated inhibition of Ras activation stimulated by
PDGF (Fig. 4A). Similarly, coincubation of mesan-
gial cells with farnesylpyrophosphate partly reduced
the e¡ect of lovastatin on Ras activation (Fig. 4A).
The GTP to GDP ratio (GTP/(GDP+GTP)U100)
in control, PDGF, lovastatin+PDGF, lovastatin+
PDGF+mevalonic acid, and lovastatin+PDGF+
farnesylpyrophosphate treated cells were 26.3, 46.5,
16.8, 38.8, and 30.1, respectively (data are average
of two experiments, each experiment done in dupli-
cate).
We further examined the e¡ect of lovastatin on
Ras activation induced by stimulation of cells with
FBS for 2 and 5 min. As shown in Fig. 4B, the
incubation of mesangial cells with lovastatin (20
WM) nearly completely blocked FBS-induced Ras ac-
tivation (5 min FBS stimulation) as measured by the
association of GTP with Ras. The coincubation of
mesangial cells with mevalonic acid (5 mM) pre-
vented lovastatin-mediated inhibition of Ras activa-
tion induced by FBS (5 min FBS stimulation, Fig.
4B, left panel). Similarly, coincubation of mesangial
cells with farnesylpyrophosphate partly prevented
lovastatin-mediated inhibition of Ras activation
induced by FBS (5 min FBS stimulation, Fig. 4B,
right panel). The GTP to GDP ratio (GTP/(GDP+
GTP)U100) in control, FBS, lovastatin+FBS, lova-
statin+FBS+mevalonic acid, and lovastatin+FBS+
farnesylpyrophosphate were 26.3, 40.4, 14.7, 37.4,
and 33.8, respectively (data are average of two
experiments, each experiment done in duplicate).
Parallel experiments performed by stimulation with
FBS for 2 min also gave similar results as compared
to 5-min stimulation of cells with FBS (data not
shown).
To assess the e¡ect of lovastatin on Ras process-
ing, we examined membrane distribution of p21Ras
in control and in cells treated with lovastatin in the
absence or presence of mevalonic acid. Incubation of
mesangial cells with lovastatin for 7 h markedly de-
creased the membrane association of p21Ras when
compared to control cells (Fig. 4C). Additionally,
coincubation with mevalonic acid protected lovasta-
tin-mediated inhibition in membrane Ras association
by 76% (Fig. 4C). The quantitative arbitrary densi-
tometric analysis of membrane Ras distribution in
control, lovastatin, and lovastatin+mevalonic acid
treated cells were 76.1, 19.2, and 57.7, respectively
(the data are average of two experiments, each ex-
periment done in duplicate).
3.6. Lovastatin inhibits mesangial cell proliferation
Previous studies have indicated that the incubation
of mesangial cells with lovastatin signi¢cantly inhib-
ited cell proliferation, and the addition of mevalonic
acid or farnesol prevented lovastatin-mediated inhi-
bition of cell proliferation [18]. However, to correlate
the alterations in mitogenic signaling (e.g., MAP ki-
nase and Ras signaling as shown above) to cell pro-
liferation, we have done additional studies examining
the e¡ect of lovastatin on mesangial cell proliferation
by measuring cell number. These studies were per-
formed by incubating quiescent mesangial cells with
FBS (5%) and lovastatin (5 WM) for 24 h in the
presence or absence of either mevalonic acid (5
mM) or farnesylpyrophosphate (5 WM). The results
indicated that lovastatin markedly inhibited FBS-in-
duced mesangial cell proliferation as assessed by
measuring cell number. Addition of either mevalonic
acid or farnesylpyrophosphate prevented the inhibi-
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tion of cell proliferation induced by lovastatin treat-
ment. The total number of cells per well (1U106) in
control, FBS, FBS+lovastatin, FBS+lovastatin+me-
valonic acid, and FBS+lovastatin+farnesylpyrophos-
phate were 0.20, 0.84, 0.47, 1.32, and 0.91, respec-
tively (data are average of two experiments, each
experiment done in duplicate). However, lovastatin
did not inhibit mesangial cell proliferation in control
unstimulated cells (cell numbers, 1U106/well : con-
trol, 0.20; control+lovastatin, 0.22).
4. Discussion
Previous in vitro studies have suggested that
HMG-CoA reductase inhibitors arrest G1 phase of
the cell cycle, and the mevalonate metabolites are
shown to be required in the activation of G1 phase
of the growth cycle [13,15,16]. Since the activation of
MAP kinase cascade appears to play a major role in
the integration and transmission of signaling events
in cell transition from G0 to G1 [29,30], it is conceiv-
able that the modulation of MAP kinase cascade
during cholesterogenesis may have a primary impact
on cell growth. In this study, we examined the role of
inhibition of cholesterol synthetic pathway and inter-
mediary precursors on the activation of mesangial
cell MAP kinase and Ras, two principal intracellular
mitogenic signaling events involved in cellular prolif-
eration. The data indicated that lovastatin signi¢-
cantly decreased FBS-, PDGF-, or EGF-induced
p42 MAP kinase activity. Comparative analysis of
the e¡ect of lovastatin in various agonist-induced
MAP kinase activity (e.g., FBS, PDGF, EGF)
showed a di¡erential inhibition of MAP kinase.
These data suggest that in mesangial cells lovastatin
did not completely abolish mitogenic signaling capa-
bilities, and cells retained adequate mitogenic signal-
ing potential required for cell growth. Removal of
lovastatin from mesangial cell cultures (after 7 h of
treatment) immediately restored normal growth in
FBS-containing media (data not shown), further con-
¢rming the growth signaling potential of mesangial
cells treated with lovastatin.
Additional studies were designed to identify puta-
tive intermediary products of cholesterol synthetic
pathway that modulate the lovastatin-mediated acti-
vation of MAP kinase. Coincubation of mesangial
cells with mevalonic acid, an immediate product of
HMG-CoA reductase reaction, prevented the inhi-
bition of MAP kinase activation by lovastatin. The
cellular metabolism of mevalonate produces a group
of isoprenoid compounds that are incorporated into
cholesterol, isopentenyl adenine, farnesylated pro-
teins, and other end products required for cellular
growth. Cholesterol, one of the primary end product
of mevalonate has been shown to be required for cell
membrane synthesis and eventual cell growth. We
have shown that the incubation of mesangial cells
with exogenous cholesterol or LDL (a physiological
vehicle for cholesterol delivery to cells) did not alter
lovastatin-induced inhibition of MAP kinase. Paral-
lel to MAP kinase studies, results from this and ear-
lier studies indicated that the coincubation of mesan-
gial cells with FBS (5^10%, serving as an exogenous
source of cholesterol) did not prevent the inhibitory
e¡ects of lovastatin on cellular growth [18]. Addition
of exogenous LDL or cholesterol also did not pre-
vent lovastatin-mediated inhibition of cell prolifera-
tion [13,18,19]. Thus, it appears that the inhibition of
MAP kinase activation and cellular growth in lova-
statin-treated mesangial cells may not be a direct
e¡ect of cholesterol availability, but rather likely re-
sulted from the inhibition of the synthesis of critical
isoprenoid intermediate(s) of mevalonate metabo-
lism. Farnesol is one of the primary isoprenoid inter-
mediates of mevalonic acid metabolism implicated in
isoprenylation of proteins involved in cell growth
[20^23]. This study demonstrated that the addition
of exogenous farnesylpyrophosphate signi¢cantly
prevented lovastatin-induced inhibition of MAP ki-
nase activity and cellular proliferation. Since Ras is
one of the major upstream regulators of MAP ki-
nase, these studies also suggest that the inhibition
of MAP kinase in lovastatin-treated cells may be
dependent on the limited availability of farnesol for
isoprenylation of Ras and its subsequent processing
and activation.
In previous studies, lovastatin or compactin
(HMG-CoA reductase inhibitors) were used to en-
hance the incorporation of exogenous radiolabeled
mevalonic acid into Ras proteins to examine the far-
nesylation of Ras and its ability to associate with
membrane and transforming activity [20,37,38]. In
human bladder carcinoma T24 cell line, lovastatin
had no e¡ect on the cellular content of p21 Ras,
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but it altered the intracellular localization of Ras,
causing its dissociation from cell membrane and
translocation toward the cytoplasm and nucleus
[28]. Lovastatin was shown to inhibit MAP kinase
and farnesylation of Ras, induced by insulin in rat
¢broblast cell line that overexpresses the human in-
sulin receptor [39]. Although these studies addressed
the role of lovastatin in Ras farnesylation and asso-
ciation to membrane, none of the earlier studies di-
rectly examined the e¡ect of lovastatin and the reg-
ulatory role of mevalonic acid or farnesol on the
agonist-induced activation of Ras (by measuring its
active GTP-bound form). Furthermore, we examined
the e¡ect of lovastatin on p21Ras processing by
measuring the membrane distribution of Ras. The
data indicated that lovastatin markedly decreased
the membrane association of Ras, and mevalonic
acid prevented lovastatin-mediated inhibition of
Ras membrane association by 76%. Parallel to these
Ras processing data, we have shown that lovastatin
blocked the activation of Ras (as measured by active
GTP-bound form of Ras and by assessing the Ras
GTP/GDP ratio) stimulated by either PDGF or FBS.
Coincubation of mesangial cells with mevalonic acid
nearly completely restored lovastatin-mediated inhi-
bition of agonist-induced Ras activation. Addition of
farnesylpyrophosphate partly, but not completely,
protected lovastatin-mediated inhibition of Ras acti-
vation. It is possible that the metabolism of exoge-
nous farnesylpyrophosphate in mesangial cells may
be at higher rate and thus may limit the availability
of adequate amounts of farnesylpyrophosphate to
manifest its maximum e¡ect. Additionally, other me-
valonate metabolites (e.g., geranylgeraniol) have also
been suggested to play an important role in PDGF-
receptor signaling and cyclin-dependent kinase-medi-
ated events [40,41].
Our studies suggest that lovastatin, by inhibiting
Ras processing and in turn the activation of Ras,
may inhibit MAP kinase and downstream nuclear
signaling events, including the activation of tran-
scription factors and protooncogenes, involved in
cellular DNA replication and growth. In preliminary
studies, we have shown that lovastatin markedly in-
hibited (60^80%) the mRNA expression of c-fos (a
protooncogene) stimulated by either EGF or FBS
(unpublished data), and thus lovastatin-mediated ef-
fects may involve series of transmembrane, cytoplas-
mic and nuclear signaling events culminating in cell
proliferation. The inhibitory e¡ects of lovastatin on
growth factor-mediated mitogenic responses may
have a profound impact on the prevention of mesan-
gioproliferative glomerular diseases that are thought
to be dependent on enhanced expression of growth
factors within the mesangial space and/or the accu-
mulation of endogenous pathobiologic factors (e.g.,
proin£ammatory cytokines, atherogenic lipoproteins,
immune complexes, etc.) which modulate growth fac-
tor synthesis and accumulation in diverse glomerular
diseases [4,42^47].
In summary, these data indicate that lovastatin, by
inhibiting the synthesis of mevalonic acid and farne-
sylpyrophosphate, inhibits Ras activation resulting in
the inhibition of MAP kinase cascade. These results
suggest that lovastatin, in addition to lowering athe-
rogenic lipoproteins (e.g., LDL) and related e¡ects
on growth factor expression or other renovascular
pathobiological events [19,48^51], may provide addi-
tional bene¢ts by inhibiting mitogenic signaling in-
volved in hypercellularity of mesangial cells in di-
verse glomerular diseases. However, further in vivo
studies are warranted to establish the role of lovasta-
tin in Ras and MAP kinase signaling processes in
mesangioproliferative diseases.
Acknowledgements
This work was supported by a Merit Review from
the Department of Veterans A¡airs and an Institu-
tional Fellowship from the National Kidney Foun-
dation of Southern California. We thank John Earle,
Merck Research Laboratories, Merck and Co., Inc.
(Rahway, NJ) for providing lovastatin.
References
[1] R.J. Glassock, S.G. Adler, H.J. Ward, A.H. Cohen, Primary
glomerular diseases, in: B.M. Brenner, F.C. Rector (Eds.),
The Kidney, Saunders, Philadelphia, 1991, pp. 1182^1279.
[2] J. Floege, M.W. Burns, C.E. Alpers, A. Yoshimura, P.
Pritzl, K. Gordon, R.A. Seifert, D.F. Bowen-Pope, W.G.
Couser, R.J. Johnson, Glomerular cell proliferation and
PDGF expression precede glomerulosclerosis in the remnant
kidney model, Kidney Int. 41 (1992) 297^309.
[3] J. Floege, E. Eng, B.A. Young, C.E. Alpers, T.B. Barrett,
BBAMCR 14443 2-3-99
B.V. Bassa et al. / Biochimica et Biophysica Acta 1449 (1999) 137^149 147
D.F. Bowen-Pope, R.J. Johnson, Infusion of PDGF or basic
FGF induces selective glomerular mesangial cell prolifera-
tion and matrix accumulation in rats, J. Clin. Invest. 92
(1993) 2952^2962.
[4] H.E. Abboud, Role of platelet-derived growth factor in renal
injury, Annu. Rev. Physiol. 57 (1995) 297^309.
[5] G.A. Kaysen, Hyperlipidemia of the nephrotic syndrome,
Kidney Int. Suppl 31 (1991) S8^S15.
[6] V.S. Kamanna, D.D. Roh, M.A. Kirschenbaum, Atherogen-
ic lipoproteins mediators of glomerular injury, Am. J. Neph-
rol. 13 (1993) 1^5.
[7] J.F. Moorhead, M. El-Nahas, M.K. Chan, Z. Varghese,
Lipid nephrotoxicity in chronic progressive glomerular and
tubulo-interstitial disease, Lancet 2 (1982) 1309^1311.
[8] W.F. Keane, B.L. Kasiske, M.P. O’Donnell, Lipids and pro-
gressive glomerulosclerosis, Am. J. Nephrol. 8 (1988) 261^
271.
[9] J.R. Diamond, A putative role of hypercholesterolemia in
progressive glomerular injury, Annu. Rev. Med. 43 (1992)
83^92.
[10] B.L. Kasiske, M.P. O’Donnell, M.P. Cleary, W.F. Keane,
Treatment of hyperlipidemia reduces glomerular injury in
obese Zucker rats, Kidney Int. 33 (1988) 667^672.
[11] K.P.G. Harris, M.L. Purkerson, J. Yates, S. Klahr, Lova-
statin ameliorates the development of glomerulosclerosis and
uremia in experimental nephrotic syndrome, Am. J. Kidney
Dis. 15 (1990) 16^23.
[12] B.L. Kasiske, M.P. O’Donnell, W.J. Gravis, W.F. Keane,
Pharmacologic treatment of hyperlipidemia reduces glomer-
ular injury in rat 5/6 nephrectomy model of chronic renal
failure, Circ. Res. 62 (1988) 367^374.
[13] K.P. Fairbanks, D.W. Larry, D.S. Goodman, Relationship
between mevalonate and mitogenesis in human ¢broblasts
stimulated with platelet-derived growth factor, J. Biol.
Chem. 259 (1984) 1546^1551.
[14] A.J.R. Habenicht, J.A. Glomset, R. Ross, Relation of cho-
lesterol and mevalonic acid to the cell cycle in smooth
muscle and swiss 3T3 cells stimulated to divide by platelet-
derived growth factor, J. Biol. Chem. 255 (1980) 5134^5140.
[15] V. Quesney-Huneeus, M.H. Wiley, M.D. Siperstein, Essen-
tial role for mevalonate synthesis in DNA replication, Proc.
Natl. Acad. Sci. U.S.A. 76 (1979) 5056^5060.
[16] V. Quesney-Huneeus, H.A. Galick, M.D. Siperstein, S.K.
Erickson, T.A. Spencer, J.A. Nelson, The dual role of me-
valonate in the cell cycle, J. Biol. Chem. 258 (1983) 378^385.
[17] J.L. Goldstein, J.A.S. Helgeson, M.S. Brown, Inhibition of
cholesterol synthesis with compactin renders growth of cul-
tured cells dependent on the low density lipoprotein recep-
tor, J. Biol. Chem. 254 (1979) 5403^5409.
[18] M.P. O’Donnell, B.L. Kasiske, Y. Kim, A. Durgaprasads-
rao, W.F. Keane, Lovastatin inhibits proliferation of rat
mesangial cells, J. Clin. Invest. 91 (1993) 83^87.
[19] G. Grandaliano, P. Biswas, G.G. Choudhury, H.E. Abboud,
Simvastatin inhibits PDGF-induced DNA synthesis in hu-
man gomerular mesangial cells, Kidney Int. 44 (1993) 503^
508.
[20] P.J. Casey, P.A. Solski, C.J. Der, J.E. Buss, p21 ras is modi-
¢ed by a farnesyl isoprenoid, Proc. Natl. Acad. Sci. U.S.A.
86 (1989) 8323^8327.
[21] K. Kiyoko, D.C. Adrienne, M.M. Hisaka, S.M. Graham,
J.E. Buss, C.H. Der, Isoprenoid addition to Ras protein is
the critical modi¢cation for its membrane association and
transforming activity, Proc. Natl. Acad. Sci. U.S.A. 89
(1992) 6403^6407.
[22] T. Mizuno, K. Kaibuchi, T. Yamamoto, M. Kawamura, T.
Sakoda, H. Fujioka, Y. Matsuura, Y. Takai, A stimulatory
GDP/GTP exchange protein for smg p21 is active on the
post-translationally processed form of c-Ki-ras p21 and
rhoA p21, Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 6442^
6446.
[23] A. Wolfman, I.G. Macara, A cytosolic protein catalyzes the
release of GDP from P21ras, Science 243 (1990) 67^69.
[24] A.B. Vojtek, S.M. Hollenberg, J.A. Cooper, Mammalian
Ras interacts directly with the serine/threonine kinase Raf,
Cell 74 (1993) 205^214.
[25] M.S. Marshall, Ras target proteins in eukaryotic cells,
FASEB J. 9 (1995) 1311^1318.
[26] S. Winitz, M. Russell, N. Qian, A. Gardner, L. Dwyer, G.L.
Johnson, Involvement of Ras and Raf in the Gi-coupled
acetylcholine muscarinic m2 receptor activation of mito-
gen-activated protein (MAP) kinase kinase and MAP kinase,
J. Biol. Chem. 268 (1993) 19196^19199.
[27] S. Kawata, T. Nagase, E. Yamasaki, H. Ishiguro, Y. Mat-
suzawa, Modulation of the mevalonate pathway and cell
growth by pravastatin and d-limonene in a human hepatoma
cell line (Hep G2), Br. J. Cancer 69 (1994) 1015^1020.
[28] M. Jakobisiak, S. Bruno, J.S. Skierski, Z. Darzynkiewicz,
Cell cycle-speci¢c e¡ects of lovastatin, Proc. Natl. Acad.
Sci. U.S.A. 88 (1991) 3628^3632.
[29] R. Seger, E.G. Krebs, The MAPK signalling cascade,
FASEB J. 9 (1995) 726^735.
[30] R.J. Davis, The mitogen-activated protein kinase signal
transduction pathway, J. Biol. Chem. 268 (1993) 14553^
14556.
[31] S. Traverse, N. Gomez, H. Paterson, C. Marshall, P. Cohen,
Sustained activation of the mitogen-activated protein (MAP)
kinase cascade may be required for di¡erentiation of PC12
cells, comparison of the e¡ects of nerve growth factor and
epidermal growth factor, Biochem. J. 288 (1992) 351^355.
[32] R. Treisman, Regulation of transcription by MAP kinase
cascades, Curr. Opin. Cell Biol. 8 (1996) 205^215.
[33] T. Kita, M.S. Brown, J.L. Goldstein, Feedback regulation of
3-hydroxy-3-methylglutaryl coenzyme A reductase in livers
of mice treated with mevinolin, a competitive inhibitor of the
reductase, J. Clin. Invest. 66 (1980) 1094^1100.
[34] T.W. Sturgill, L.B. Ray, N.G. Anderson, A.K. Erickson,
Methods Enzymol. 200 (1991) 342^351.
[35] J. Downward, J.D. Graves, P.H. Warne, S. Rayter, D.A.
Cantrell, Stimulation of p21ras upon T-cell activation, Na-
ture 346 (1990) 719^723.
[36] E.C. Lerner, Y. Qian, A.D. Hamilton, S.M. Sebti, Disrup-
tion of oncogenic K-Ras4B processing and signaling by a
BBAMCR 14443 2-3-99
B.V. Bassa et al. / Biochimica et Biophysica Acta 1449 (1999) 137^149148
potent geranylgeranyltransferase I inhibitor, J. Biol. Chem.
270 (1995) 26770^26773.
[37] J.H. Jackson, C.G. Cochrane, J.R. Bourne, P.A. Solski, J.E.
Buss, C.J. Der, Farnesol modi¢cation of Kirsten-ras exon 4B
protein is essential for transformation, Proc. Natl. Acad. Sci.
U.S.A. 87 (1990) 3042^3046.
[38] P.L. Crowell, R.R. Chang, Z. Ren, C.E. Elson, M.N. Gould,
Selective inhibition of isoprenylation of 21^26-kDa proteins
by the anticarcinogen d-limonene and its metabolites, J. Biol.
Chem. 266 (1991) 17679^17685.
[39] X. Xu, T.F. McGuire, M.A. Blaskovich, S.M. Sebti, G. Ro-
mero, Lovastatin inhibits the stimulation of mitogen-acti-
vated protein kinase by insulin in HIRcB ¢broblasts, Arch.
Biochem. Biophys. 326 (1996) 233^237.
[40] T.F. McGuire, Y. Qian, A. Vogt, A.D. Hamilton, S.M.
Sebti, Platelet-derived growth factor receptor tyrosine phos-
phorylation requires protein geranylgeranylation but not far-
nesylation, J. Biol. Chem. 271 (1996) 27402^27407.
[41] A. Hirai, S. Nakamura, Y. Noguchi, T. Yasuda, M. Kita-
gawa, I. Tatsuno, T. Oeda, K. Tahara, T. Terano, S. Nar-
umiya, L.D. Kohn, Y. Saito, Geranylgeranylated Rho small
GTPase(s) are essential for the degradation of p27kip1 and
facilitates the progression from G1 to S phase in growth-
stimulated rat FRTL-5 cells, J. Biol. Chem. 272 (1997) 13^
16.
[42] L. Gesualdo, M. Pinzani, J.J. Floriano, M.O. Hassan, N.U.
Nugy, F.P. Schena, S.N. Emancipator, H.E. Abboud, Plate-
let-derived growth factor expression in mesangial prolifera-
tive glomerulonephritis, Lab. Invest. 65 (1991) 160^167.
[43] B. Fellstrom, L. Klareskog, C.H. Heldin, E. Larsson, L.
Ronnstrand, L. Terracio, G. Tufveson, J. Wahlberg, K. Ru-
bin, Platelet-derived growth factor receptors in the kidney,
upregulated expression in in£ammation, Kidney Int. 36
(1989) 1099^1102.
[44] H. Iida, R. Seifert, C.E. Alpers, R.G.K. Gronwald, P.E.
Phillips, P. Pritzl, K. Gordon, A.M. Gown, R. Ross, D.F.
Bowen-Pope, R.J. Johnson, Platelet-derived growth factor
and PDGF receptor are induced in mesangial proliferative
nephritis in the rat, Proc. Natl. Acad. Sci. U.S.A. 88 (1991)
6560^6564.
[45] V.S. Kamanna, B.V. Bassa, M.A. Kirschenbaum, Athero-
genic lipoproteins and human disease: extending concepts
beyond the heart to the kidney, Curr. Opin. Nephrol. Hyper-
tens. 6 (1997) 205^211.
[46] J. Egido, M. Gomez-Chiarri, A. Ortiz, C. Bustos, J. Alonso,
C. Gomez-Guerrero, D. Gomez-Garre, M.S. Lopez-Armada,
J. Plaza, E. Gonzalez, Role of tumor necrosis factor-K in the
pathogenesis of glomerular diseases, Kidney Int. 43 (1993)
S59^S64.
[47] E.J. Battegay, E.W. Raines, T. Colbert, R. Ross, TNF-K
stimulation of ¢broblast proliferation. Dependence on plate-
let-derived growth factor (PDGF) secretion and PDGF re-
ceptor expression, J. Immunol. 154 (1995) 6040^6047.
[48] H. Ha, D.D. Roh, M.A. Kirschenbaum, V.S. Kamanna,
Atherogenic lipoproteins enhance mesangial cell PDGF ex-
pression. Role of protein tyrosine kinase and cyclic AMP
dependent protein kinase A, J. Lab. Clin. Med. 131 (1998)
456^465.
[49] E.F. Grone, H.E. Abboud, M. Hohne, A.K. Walli, H.J.
Grone, D. Stuker, H. Robenek, E. Wieland, D. Seidel, Ac-
tions of lipoproteins in cultured human mesangial cells,
modulation by mitogenic vasoconstrictors, Am. J. Physiol.
263 (1992) F686^F696.
[50] A. Stiko-Rahm, A. Hultgardh-Nilsson, J. Regnstrom, A.
Hamsten, J. Nilsson, Native and oxidized LDL enhances
production of PDGF AA and the surface expression of
PDGF receptors in cultured human smooth muscle cells,
Arterioscl. Thromb. 12 (1992) 1099^1109.
[51] V.S. Kamanna, R. Pai, D.D. Roh, M.A. Kirschenbaum,
Oxidative modi¢cation of low density lipoprotein enhances
the murine mesangial cell cytokines associated with mono-
cyte migration, di¡erentiation and proliferation, Lab. Invest.
74 (1996) 1067^1079.
BBAMCR 14443 2-3-99
B.V. Bassa et al. / Biochimica et Biophysica Acta 1449 (1999) 137^149 149
